Author: Antonini Giovanni Cox Maria Montefusco Enrico Ferrari Antonella Conte Esmeralda Morino Stefania Latino Pamela Trasimeni Guido Monarca Bruno
Publisher: Springer Publishing Company
ISSN: 0167-594X
Source: Journal of Neuro-Oncology, Vol.81, Iss.2, 2007-01, pp. : 197-199
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patient showed significant clinical improvement and Cerebro spinal fluid (CSF) clearance of lymphomatous cells. A MRI scan performed after 30 days from the start of therapy showed full regression of lymphomatous infiltration. This report confirms the efficacy and safety of IT RTX in the treatment of CNS B-cell NHL.
Related content
By Cavalli-Björkman Nina Ösby Eva Lundin Jeanette Kalin Mats Österborg Anders Gruber Astrid
Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. :
Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. :
By Sebastian Martin Passlick Bernward Friccius-Quecke Hilke Jäger Michael Lindhofer Horst Kanniess Frank Wiewrodt Rainer Thiel Eckhard Buhl Roland Schmittel Alexander
Cancer Immunology, Immunotherapy, Vol. 56, Iss. 10, 2007-10 ,pp. :